Business Leaders Review - The Heart and Strategy Behind Altasciences' Marketing Evolution
Alta Sciences
JULY 3, 2025
All Rights Reserved. Cookie Policy | Privacy Policy Have a question? × Id be happy to help.
Alta Sciences
JULY 3, 2025
All Rights Reserved. Cookie Policy | Privacy Policy Have a question? × Id be happy to help.
Perficient: Drug Development
FEBRUARY 27, 2024
Imagine this: You are a marketer at a medical device organization. It’s every marketer’s dream. Let’s look at a few ways medical device marketers can supercharge the digital product catalogs. Perhaps there is a text-based testimonial by a loyal user or a video giving a glimpse of the manufacturing and QA process.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Agency IQ
JUNE 29, 2023
to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. To implement that authority, FDA published a final rule in the Federal Register on September 15, 2015 [80 FR 55237] which revised 21 CFR 1.94
The Pharma Data
MAY 13, 2021
The way this was done, was through webinars. I know you may be asking, “What is a webinar”? A webinar is an online video presentation that is focused on great practical information which you sit back and view on your PC, Mac, iPod or iPad. Plus, most webinars you canâ??t I was at a fitness site and watched a free webinar.
Agency IQ
OCTOBER 27, 2023
to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. the drug and device) of the combination product. The final rule will amend the administrative destruction provisions in 21 CFR 1.94 to include devices.
Agency IQ
SEPTEMBER 29, 2023
Due to the presence of nitrosamines in certain drug products, FDA had required that drug manufacturers conduct an initial risk assessment of approved or marketed products, with an initial completion date of October 1, 2021, and then confirmatory testing due by October 1, 2023. AgencyIQ October 1 Nitrosamine testing due to FDA.
Agency IQ
DECEMBER 1, 2023
to provide notice and an opportunity for owners or consignees of the drug to appear before the Agency and introduce testimony prior to the destruction of their drug. Prohaska, Kavita C. and Annex 1 Conference Joel Welch December 12 AgencyIQ Looking ahead to 2024: Regulatory Forecast for the U.S. to include devices.
Let's personalize your content